Clinical Trial Update: Romidepsin and Parsaclisib for the Treatment of Relapsed or Refractory T-Cell Lymphomas [Phase 1]

View source ↗

Summary

Phase 1 trial update evaluating the combination of romidepsin and parsaclisib for relapsed or refractory T-cell lymphomas; the study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Large Cell Lymphoma
• Cutaneous T-cell Non-hodgkin Lymphoma
• Mature T-cell and Nk-cell Non-hodgkin Lymphoma
• Mycosis Fungoides
• T-cell Non-hodgkin Lymphoma
• Transformed Mycosis Fungoides

Drugs mentioned

• Parsaclisib (parsaclisib)
• Romidepsin (romidepsin)

Snippet

Sponsor: Walter Hanel | Conditions: Recurrent Anaplastic Large Cell Lymphoma, Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma | Phase 1 | Status: COMPLETED